PubRank

M Gent

Author PubWeight™ 295.08‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The Burlington randomized trial of the nurse practitioner. N Engl J Med 1974 17.02
2 Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999 12.75
3 Controversy in counting and attributing events in clinical trials. N Engl J Med 1979 7.25
4 Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995 6.86
5 Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991 6.55
6 A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999 5.14
7 Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000 4.81
8 A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996 4.70
9 PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998 4.52
10 The Burlington randomized trial of the nurse practitioner: health outcomes of patients. Ann Intern Med 1974 4.37
11 Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000 4.12
12 Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003 3.94
13 Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. Eur Heart J 2000 3.71
14 A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993 3.67
15 Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994 3.51
16 Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 2000 3.50
17 Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984 3.47
18 Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997 3.40
19 Effect of bromhexine on ventilatory capacity in patients with a variety of chest diseases. Lancet 1969 3.34
20 Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med 2000 3.32
21 Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982 3.16
22 Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985 2.99
23 Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979 2.91
24 Significance testing to establish equivalence between treatments, with special reference to data in the form of 2X2 tables. Biometrics 1977 2.87
25 Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction. N Engl J Med 1996 2.69
26 Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med 1998 2.49
27 The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. J Am Coll Cardiol 1999 2.44
28 Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988 2.44
29 Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000 2.35
30 Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post-arthroplasty screening study. A randomized, controlled trial. Ann Intern Med 1997 2.28
31 Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med 1989 2.28
32 Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest 2001 2.25
33 How should results from completed studies influence ongoing clinical trials? The CAFA Study experience. Ann Intern Med 1991 2.06
34 Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. Circulation 2000 2.05
35 Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol 1988 1.93
36 Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 2009 1.91
37 Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991 1.81
38 Depression and risk of sudden cardiac death after acute myocardial infarction: testing for the confounding effects of fatigue. Psychosom Med 2000 1.80
39 Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000 1.71
40 Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation 2001 1.70
41 Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study. Circulation 1991 1.68
42 Expectorant action of bromhexine in chronic obstructive bronchitis. Br Med J 1970 1.67
43 A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986 1.67
44 A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 1993 1.64
45 Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982 1.64
46 Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J 2001 1.62
47 BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005 1.60
48 Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost 2001 1.58
49 The effect of thrombocytopenia on experimental arteriosclerotic lesion formation in rabbits. Smooth muscle cell proliferation and re-endothelialization. J Clin Invest 1977 1.58
50 Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990 1.56
51 Dual-chamber versus ventricular pacing. Critical appraisal of current data. Circulation 1996 1.55
52 Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology 2001 1.55
53 Emergency department use at two Hamilton hospitals. Can Med Assoc J 1975 1.55
54 Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA 1990 1.55
55 Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med 1997 1.54
56 Intermittent compression units for severe post-phlebitic syndrome: a randomized crossover study. CMAJ 1999 1.52
57 Cyclophosphamide and plasma exchange in multiple sclerosis. Lancet 1991 1.50
58 The occurrence of subsequent malignancy in patients presenting with deep vein thrombosis: results from a historical cohort study. Thromb Haemost 1998 1.49
59 Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf 1999 1.46
60 Relationship between acute respiratory illness and air pollution levels in an industrial city. Am Rev Respir Dis 1977 1.46
61 Coronary patency, infarct size and left ventricular function after thrombolytic therapy for acute myocardial infarction: results from the tissue plasminogen activator: Toronto (TPAT) placebo-controlled trial. TPAT Study Group. J Am Coll Cardiol 1991 1.45
62 Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995 1.44
63 Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. Psychosom Med 1999 1.40
64 The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988 1.39
65 1965-1990: 25th anniversary of nurse practitioners. A classic manuscript reprinted in celebration of 25 years of progress. The Burlington randomized trial of the nurse practitioner. 1971-2. J Am Acad Nurse Pract 1990 1.38
66 A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990 1.32
67 An emergency department triage model based on presenting complaints. Can J Public Health 1973 1.29
68 Prevention and treatment of postphlebitic syndrome: results of a 3-part study. Arch Intern Med 2001 1.28
69 Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987 1.25
70 Sensitivity and specificity of a rapid whole-blood assay for D-dimer in the diagnosis of pulmonary embolism. Ann Intern Med 1998 1.24
71 The stroke prognosis instrument II (SPI-II) : A clinical prediction instrument for patients with transient ischemia and nondisabling ischemic stroke. Stroke 2000 1.24
72 The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 1989 1.22
73 When is a prognostic factor useful? A guide for the perplexed. J Clin Oncol 1991 1.20
74 Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005 1.19
75 Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing. CTOPP Investigators. J Am Coll Cardiol 2001 1.19
76 Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety. Ann Intern Med 1987 1.16
77 Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost 2004 1.14
78 Prevention of venous thrombosis with small, subcutaneous doses of heparin. JAMA 1976 1.13
79 Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 1988 1.13
80 Relevance of preoperative and postoperative blood tests to postoperative leg-vein thrombosis. Lancet 1973 1.11
81 The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982 1.10
82 A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994 1.09
83 Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost 1996 1.09
84 Replacement of venography in suspected venous thrombosis by impedance plethysmography and 125I-fibrinogen leg scanning: a less invasive approach. Ann Intern Med 1981 1.09
85 The qualification and disqualification of patients and events in long-term cardiovascular clinical trials. Thromb Haemost 1979 1.08
86 Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial. Ann Intern Med 1987 1.08
87 Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977 1.04
88 A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer. J Clin Oncol 1990 1.04
89 Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation 1999 1.03
90 Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. N Engl J Med 1974 1.02
91 Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. J Thromb Haemost 2007 1.02
92 Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. J Thromb Haemost 2007 1.01
93 A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study. Ann Intern Med 1992 1.00
94 The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Circulation 1975 0.99
95 Clinical validity of a negative venogram in patients with clinically suspected venous thrombosis. Circulation 1981 0.99
96 The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme. J Bone Joint Surg Br 2012 0.98
97 A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med 1989 0.98
98 Social class and emergency department utilization. Can Fam Physician 1975 0.97
99 Impedance plethysmography using the occlusive cuff technique in the diagnosis of venous thrombosis. Circulation 1976 0.97
100 Controversy in neurology: the Canadian study on TIA and aspirin. A critique of the Canadian TIA study. Reply. Ann Neurol 1979 0.97
101 An alternative to the use of two-sided tests in clinical trials. Stat Med 1996 0.97
102 Wound botulism in injectors of drugs: upsurge in cases in England during 2004. Euro Surveill 2005 0.96
103 Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 1998 0.96
104 The diagnosis of acute, recurrent, deep-vein thrombosis: a diagnostic challenge. Circulation 1983 0.94
105 Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med 2000 0.94
106 Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2005 0.94
107 A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. Stroke 1985 0.93
108 The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Arch Intern Med 1998 0.93
109 Canadian Implantable Defibrillator Study (CIDS): study design and organization. CIDS Co-Investigators. Am J Cardiol 1993 0.92
110 Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001 0.92
111 Absorption and antidysrhythmic activity of oral disopyramide phosphate after acute myocardial infarction. Br J Clin Pharmacol 1982 0.91
112 Effectiveness of intermittent pulsatile elastic stockings for the prevention of calf and thigh vein thrombosis in patients undergoing elective knee surgery. Thromb Res 1979 0.91
113 Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: the Canadian implantable defibrillator study. Circulation 2001 0.91
114 Synergism between ipratropium and theophylline in asthma. Thorax 1981 0.91
115 Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (third of three parts). N Engl J Med 1975 0.90
116 On the probability of a committee meeting. Br Med J 1976 0.90
117 Regression of injury-induced atheromatous lesions in rabbits. Arch Pathol Lab Med 1976 0.88
118 Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial. Chest 1990 0.88
119 Intra-uterine infection and cord immunoglobulin M. II. Clinical analysis of infants with elevated cord serum immunoglobulin M. Can Med Assoc J 1974 0.86
120 Coronary care unit utilization in Hamilton, Ontario, a city of 375,000 people. Can J Cardiol 1988 0.86
121 Accuracy of screening compression ultrasonography and clinical examination for the diagnosis of deep vein thrombosis after total hip or knee arthroplasty. Can J Surg 1998 0.86
122 Methotrexate in rheumatoid arthritis. Feedback on American College of Physicians guidelines. Ann Intern Med 1989 0.86
123 North American Vasovagal Pacemaker Study: study design and organization. Pacing Clin Electrophysiol 1997 0.84
124 Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch Intern Med 1999 0.84
125 Prevention of deep vein thrombosis in potential neurosurgical patients. A randomized trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control. Arch Intern Med 1989 0.84
126 Relationship between pacemaker dependency and the effect of pacing mode on cardiovascular outcomes. Circulation 2001 0.84
127 Adverse haematological effects of ticlopidine. Prevention, recognition and management. Drug Saf 1998 0.84
128 Early treatment of stroke with monosialoganglioside GM-1. Efficacy and safety results of the Early Stroke Trial. Stroke 1994 0.83
129 Canadian American ticlopidine study (cats) in thromboembolic stroke. Agents Actions Suppl 1984 0.83
130 Relationship between the antithrombotic and anticoagulant effects of low molecular weight heparin. Thromb Res 1981 0.83
131 Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction. J Am Coll Cardiol 1989 0.83
132 The influence of red blood cells on the effects of aspirin or sulphinpyrazone on platelet adherence to damaged rabbit aorta. Br J Haematol 1979 0.83
133 Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (first of three parts). N Engl J Med 1975 0.83
134 Antithrombotic therapy for cerebrovascular disorders. An update. Chest 1995 0.82
135 An evaluation of impedance plethysmography and 125I-fibrinogen leg scanning in patients following hip surgery. Thromb Haemost 1989 0.82
136 The defibrillator in acute myocardial infarction trial (DINAMIT): study protocol. Am Heart J 2000 0.82
137 A randomized trial of aspirin and sulfinpyrazone in patients with threatened stroke. Results and methodologic issues. Circulation 1980 0.82
138 XIV. Cerebral ischemia: the role of thrombosis and of antithrombotic therapy. Study group on antithrombotic therapy. Stroke 1977 0.82
139 Failure of aspirin plus dipyridamole to prevent restenosis after carotid endarterectomy. Ann Intern Med 1992 0.82
140 Evaluation of disodium cromoglycate in intrinsic and extrinsic asthma. Am Rev Respir Dis 1972 0.81
141 The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med 1996 0.81
142 Intrauterine infection and cord immunoglobulin M. I. Analysis of methods of assay and levels of immunoglobulin M in normal newborns. Can Med Assoc J 1972 0.81
143 One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina or other chest pain in Hamilton, Ontario, a city of 375,000 people. Can J Cardiol 1989 0.81
144 Anticholinergic and sympathomimetic combination therapy of asthma. J Allergy Clin Immunol 1983 0.81
145 Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review. J Thromb Haemost 2004 0.81
146 Single studies and overview analyses: is aspirin of value in cerebral ischemia? Stroke 1987 0.81
147 Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med 1999 0.81
148 Resolution of lipid-containing atherosclerotic lesions induced by injury. Blood Vessels 1977 0.81
149 An evaluation of suloctidil in the prevention of deep vein thrombosis in neurosurgical patients. Thromb Res 1985 0.81
150 Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study. Circulation 1996 0.81
151 Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery. Arch Intern Med 1996 0.81
152 Prevention of venous thrombosis by intermittent sequential calf compression in patients with intracranial disease. Thromb Res 1979 0.80
153 Differing patterns of cholesterol accumulation and 3-H-cholesterol influx in areas of the cholesterol-fed pig aorta identified by evans blue dye. Exp Mol Pathol 1975 0.80
154 A meta-analysis of the studies of dihydroergotamine plus heparin in the prophylaxis of deep vein thrombosis. Chest 1986 0.80
155 The diagnostic value of the fibrinogen/fibrin fragment E antigen assay in clinically suspected deep vein thrombosis. Blood 1982 0.80
156 Maprotiline (Ludiomil, Ciba 34,276-BA) and imipramine in depressed outpatients: a double-blind clinical study. Curr Ther Res Clin Exp 1976 0.80
157 Low dose cyclosporine in rheumatoid arthritis: a pilot study. J Rheumatol 1987 0.80
158 Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies). J Rheumatol 1994 0.79
159 Enhanced platelet accumulation onto injured carotid arteries in rabbits after aspirin treatment. J Clin Invest 1981 0.79
160 The osmotic fragility of mammalian erythrocytes in hypotonic solutions of sodium chloride. Comp Biochem Physiol 1969 0.79
161 Design and baseline results of the monosialoganglioside early stroke trial. The EST Study Group. Stroke 1992 0.79
162 The current status of platelet suppressive drugs in the treatment of thrombosis. Thromb Diath Haemorrh 1975 0.79
163 Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994 0.79
164 Sex-related differences in platelet aggregation: influence of the hematocrit. Blood 1980 0.79
165 Effects of immunosuppression with cyclosporine in insulin-dependent diabetes mellitus of recent onset: the Canadian open study at 44 months. Transplant Proc 1988 0.78
166 Antithrombotic therapy for cerebrovascular disorders. Chest 1992 0.78
167 Ultrasonographic screening for deep vein thrombosis following arthroplasty fails to reduce posthospital thromboembolic complications: the Postarthroplasty Screening Study (PASS). Chest 1998 0.78
168 Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation. J Clin Oncol 1995 0.78
169 Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol 1997 0.78
170 A placebo-controlled study to determine the efficacy of oral disopyramide phosphate for the prophylaxis of ventricular dysrhythmias after acute myocardial infarction. Br J Clin Pharmacol 1982 0.78
171 Critical evaluation of platelet-inhibiting drugs in thrombotic disease. Prog Hematol 1975 0.78
172 Alanine transport across the human placental brush border membrane and the role of SH groups in carrier function. Z Ernahrungswiss 1995 0.77
173 The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1,984 patients. Canadian Collaborative Group. Chest 1998 0.77
174 Increased dipyridamole plasma concentrations associated with salicylate administration. Relationship to effects on platelet aggregation in vivo. Thromb Res 1979 0.77
175 Comparison of mortality from acute myocardial infarction between 1979 and 1992 in a geographically defined stable population. Am J Cardiol 1996 0.77
176 Metoprolol prophylaxis against postoperative atrial fibrillation increases length of hospital stay in patients not on pre-operative beta blockers: the beta blocker length of stay (BLOS) trial. Heart 2004 0.77
177 Utility of ultrasound imaging of the lower extremities in the diagnostic approach in patients with suspected pulmonary embolism. J Intern Med 2001 0.76
178 Interaction between cyclosporin A and nonsteroidal antiinflammatory drugs. J Rheumatol 1997 0.76
179 Platelet-inhibiting drugs iee parts). N Engl J Med 1975 0.76
180 Resolution of experimental pulmonary emboli with heparin and streptokinase in different dosage regimens. J Clin Invest 1974 0.76
181 Clinical trials of cyclosporin in IDDM. Diabetes Care 1989 0.76
182 Randomized trial of therapy with platelet antiaggregants for threatened stroke. 2: Observations on the pathogenesis and natural history of threatened stroke. Can Med Assoc J 1980 0.75
183 Amiodarone for patients with ventricular premature depolarizations after myocardial infarction. Is it safe to stop treatment at one year? Circulation 1993 0.75
184 The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation. Br J Cancer 1992 0.75
185 Effects of cyclosporine in recent-onset juvenile type 1 diabetes: impact of age and duration of disease. J Pediatr 1987 0.75
186 1. Design and main results of the trial. Can Med Assoc J 1980 0.75
187 Effect of suloctidil on platelet function in patients with shortened platelet survival time. Thromb Res 1984 0.75
188 The effect of ipratropium on exercise-induced bronchoconstriction. Ann Allergy 1981 0.75
189 The 'parent/child game': an innovative approach to parenting assessment and training with relevance to child abuse cases. Nurs Stand Spec Suppl 1991 0.75
190 Impact of tissue plasminogen activator and heparin versus heparin alone on quantitative coronary angiographic findings in myocardial infarction. The Toronto Tissue Plasminogen Activator Trial Study Group. Am J Cardiol 1993 0.75
191 Heparin therapy for deep vein thrombosis: from hospital to home. Am J Med 2001 0.75
192 Clopidogrel, aspirin, and first line therapy. Cerebrovasc Dis 1998 0.75
193 Antibiotics in sinus secretions. Lancet 1968 0.75
194 Lidocaine and the reduction of post-venographic pain. Aust N Z J Med 1984 0.75
195 Graded exercise testing following thrombolytic therapy for acute myocardial infarction: the importance of timing and infarct location. TPAT Study Group. Can J Cardiol 1994 0.75
196 The identical effect of electrolyte and non-electrolyte on the osmotic fragility of mammalian erythrocytes. Comp Biochem Physiol 1970 0.75
197 Parenting assessment: the parent/child game. Nurs Stand 1992 0.75
198 Definition of high risk/high response population for stroke in patients with transient ischemic attacks. Thromb Haemost 1979 0.75
199 Making research relevant: experience in a Canadian health region. Med J Aust 1977 0.75
200 Clomipramine HCL--a double-blind study of a new antidepressant drug. Can Psychiatr Assoc J 1973 0.75
201 Kids and car seats. Can Nurse 1993 0.75
202 Relationships between osmotic fragility and other species-specific variables of mammalian erythrocytes. Comp Biochem Physiol 1970 0.75
203 Platelet tests and antiplatelet drugs in coronary artery disease. Circulation 1983 0.75
204 Problem oriented medical records: their impact on staff communication, attitudes and decision making. Arch Phys Med Rehabil 1975 0.75
205 Clomipramine (Anafranil) in depressive patients with obsessive neurosis. J Int Med Res 1977 0.75
206 Thrombolysis with a combination of small doses of streptokinase and full doses of heparin. Semin Thromb Hemost 1975 0.75
207 Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT): rationale and protocol. CAMIAT Investigators. Am J Cardiol 1993 0.75
208 The spectrum of ABO hemolytic disease of the newborn infant. J Pediatr 1979 0.75
209 Guidelines on the management of secondary prophylaxis of vascular events in stable patients in primary care. Int J Clin Pract 2004 0.75
210 The Canadian cooperative study of platelet suppressant therapy in threatened stroke. Thromb Haemost 1979 0.75
211 Effects on thrombin generation of single injections of Hirulog in patients with calf vein thrombosis. Thromb Haemost 1994 0.75
212 Antiplatelet therapy: views from the experts. Neurology 1999 0.75
213 Colchicine treatment of cirrhosis: answers. Hepatology 1989 0.75
214 The relationship between basic biomedical research and the design and analysis of clinical trials. Thromb Res Suppl 1983 0.75
215 Immunosuppression and type I diabetes. Lancet 1987 0.75